Skip Navigation LinksHome > March 2014 - Volume 26 - Issue 2 > Screening for lung cancer
Current Opinion in Oncology:
doi: 10.1097/CCO.0000000000000055
LUNG AND MEDIASTINUM: Edited by Robert Pirker

Screening for lung cancer

Prosch, Helmuta; Schaefer-Prokop, Corneliab

Collapse Box


Purpose of review: The purpose of this review is to provide an update on the current data about low-dose computed tomography (LD-CT) lung cancer screening.

Recent findings: The National Lung Screening Trial (NLST) was the first study that provided statistical evidence that LD-CT screening for lung cancer significantly reduces lung cancer mortality by 20%. Three statistically underpowered European trials could not confirm the positive effect of LD-CT screening on lung cancer mortality. Major obstacles in lung cancer screening are overdiagnosis and the large number of false-positive results. In the NLST, more than 24% of the screens were positive, most of which (96.4%) proved to be benign in nature. Optimized protocols for the workup of detected nodules may help to reduce the number of false-positive screens.

Summary: Currently, the NLST is the only sufficiently powered trial to report a lower mortality rate with LD-CT screening. Long-term follow-up data are still anticipated on the European screening trials. Furthermore, data on the extent of the potential dangers of LD-CT screening, such as overdiagnosis, false-positive results, and the effect of cumulative radiation dose, have yet to be investigated thoroughly.

© 2014 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.